ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,927.34
      -0.73%
      US Tech 100
      20,696.80
      -0.98%
      Dow Jones
      42,674.68
      -0.74%
      Brent Oil
      74.44
      1.11%
      Bitcoin
      92,368.98
      -1.23%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. AnaptysBio Inc (ANAB) Quote

      AnaptysBio Inc

      AnaptysBio Inc (ANAB)

      NASDAQ
      12.79
      -0.25
      ( -1.92% )
      Updated: 12:11:17
      Delayed by 15 minutes

      Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

      Premium

      Key stats and details

      Current Price
      12.79
      Bid
      12.79
      Ask
      12.88
      Volume
      189,294
      12.51 Day's Range 13.03
      12.51 52 Week Range 41.3083
      Market Cap
      389.183M
      Previous Close
      13.04
      Open
      13.005
      Last Trade
      1
      @
      12.783
      Last Trade Time
      12:13:11
      Financial Volume
      $ 2,412,889
      VWAP
      12.7468
      Average Volume (3m)
      589,597
      Shares Outstanding
      30,428,682
      Dividend Yield
      -
      PE Ratio
      -2.38
      Earnings Per Share (EPS)
      -5.38
      Revenue
      17.16M
      Net Profit
      -163.62M

      About AnaptysBio Inc

      AnaptysBio Inc is clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery techno... AnaptysBio Inc is clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product candidates are ANB020, ANB019, and Checkpoint receptor agonist. The entity generates revenue from the collaborative research and development arrangements. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.anaptysbio.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      -
      AnaptysBio Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ANAB. The last closing price for AnaptysBio was $13.04. Over the last year, AnaptysBio shares have traded in a share price range of $ 12.51 to $ 41.3083.

      AnaptysBio currently has 30,428,682 shares outstanding. The market capitalization of AnaptysBio is $396.79 million. AnaptysBio has a price to earnings ratio (PE ratio) of -2.38.

      Ask ADVFN Intelligence (AI)

      ANAB Latest News

      More News

      Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

      December 18 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      December 11 2024
      Edgar (US Regulatory)

      Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis

      ANB032 was well tolerated across all doses with no safety signals observedAD trial and all further investment in ANB032 will be discontinuedAnticipate top-line Phase 2b data in rheumatoid...

      December 11 2024
      GlobeNewswire Inc.

      Form EFFECT - Notice of Effectiveness

      November 18 2024
      Edgar (US Regulatory)

      Form 424B5 - Prospectus [Rule 424(b)(5)]

      November 15 2024
      Edgar (US Regulatory)

      Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

      November 14 2024
      Edgar (US Regulatory)

      Form S-3 - Registration statement under Securities Act of 1933

      November 05 2024
      Edgar (US Regulatory)

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]

      November 05 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      November 05 2024
      Edgar (US Regulatory)

      Anaptys Announces Participation in November and December Investor Conferences

      SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced...

      November 05 2024
      GlobeNewswire Inc.
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-1.69-11.671270718214.4814.7212.5141087313.66871891CS
      4-10.73-45.620748299323.5225.8812.5180394917.526142CS
      12-21.19-62.360211889333.9836.5412.5158959721.65783157CS
      26-12.21-48.842541.308312.5143887826.51655404CS
      52-8.42-39.698255539821.2141.308312.5138670525.19316037CS
      156-22.2-63.446699056934.9941.308312.5129715123.85763996CS
      260-3.87-23.229291716716.6641.308311.9531225522.77641782CS

      ANAB - Frequently Asked Questions (FAQ)

      What is the current AnaptysBio share price?
      The current share price of AnaptysBio is $ 12.79
      How many AnaptysBio shares are in issue?
      AnaptysBio has 30,428,682 shares in issue
      What is the market cap of AnaptysBio?
      The market capitalisation of AnaptysBio is USD 396.79M
      What is the 1 year trading range for AnaptysBio share price?
      AnaptysBio has traded in the range of $ 12.51 to $ 41.3083 during the past year
      What is the PE ratio of AnaptysBio?
      The price to earnings ratio of AnaptysBio is -2.38
      What is the cash to sales ratio of AnaptysBio?
      The cash to sales ratio of AnaptysBio is 22.69
      What is the reporting currency for AnaptysBio?
      AnaptysBio reports financial results in USD
      What is the latest annual turnover for AnaptysBio?
      The latest annual turnover of AnaptysBio is USD 17.16M
      What is the latest annual profit for AnaptysBio?
      The latest annual profit of AnaptysBio is USD -163.62M
      What is the registered address of AnaptysBio?
      The registered address for AnaptysBio is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
      What is the AnaptysBio website address?
      The website address for AnaptysBio is www.anaptysbio.com
      Which industry sector does AnaptysBio operate in?
      AnaptysBio operates in the PHARMACEUTICAL PREPARATIONS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      NXUNXU Inc
      $ 1.42
      (483.40%)
      		395.26M
      WATTEnergous Corporation
      $ 1.63
      (296.40%)
      		161.3M
      INTZIntrusion Inc
      $ 5.8262
      (169.73%)
      		112.67M
      CYNCYNGN Inc
      $ 1.2602
      (100.70%)
      		59.04M
      HOLOMicroCloud Hologram Inc
      $ 4.745
      (97.71%)
      		94.91M
      ABPAbpro Holdings Inc
      $ 2.10
      (-53.23%)
      		1.35M
      TRAWTraws Pharma Inc
      $ 7.7117
      (-42.54%)
      		885.71k
      LITMSnow Lake Resources Ltd
      $ 1.1296
      (-29.40%)
      		44.19M
      LGHLWLion Group Holding Ltd
      $ 0.0052
      (-25.71%)
      		54.78k
      BITSGlobal X Blockchain and Bitcoin Stratagy ETF
      $ 66.81
      (-24.48%)
      		8.74k
      NXUNXU Inc
      $ 1.42
      (483.40%)
      		395.26M
      VINCVincerx Inc
      $ 0.3575
      (84.28%)
      		293.96M
      XTIAXTI Aerospace Inc
      $ 0.04
      (1.27%)
      		173.53M
      WATTEnergous Corporation
      $ 1.63
      (296.40%)
      		161.3M
      SMXSMX Security Matters Public Company
      $ 0.5885
      (66.43%)
      		125.73M

      ANAB Discussion

      View Posts
      Monksdream Monksdream 3 months ago
      ANAB definite uptrend
      👍️0
      gfp927z gfp927z 3 years ago
      HighPeaks, The NY Times article was high profile, but the connection to ANAB isn't readily apparent.

      Even with the partial sale/monetization of the revenue stream from dostarlimab in December, the drug is also being studied by Glaxo for other cancer types (endometrial, non-small cell lung, ovarian, and mismatch repair deficient solid tumors). One question to answer is whether the monetization deal with Sagard was only for colorectal, or for all the indications? Probably for all, but I'll have to do more research.

      ANAB has numerous other programs and a large pile of cash, so looks interesting. But investing in biotech requires a ton of research, but even then you still don't know what you have, and landmines are everywhere. Better to invest in 'what you know', as Buffett recommends :o)




      ---
      👍️0
      HighPeaks HighPeaks 3 years ago
      Thanks TP. Yeah this has the potential to really be a big mover. So surprised no one has made the connection between this potential miracle drug and $ANAB receiving royalties on it(as it’s originator). GSK is the collaborator who has just commercialized it but it’s ANAB invention.
      👍️0
      tedpeele tedpeele 3 years ago
      Tremendous find HighPeaks. .You have been early on quite a few big movers. I'm thinking this is yet another one.

      Will be watching this closely...thanks.
      👍️0
      HighPeaks HighPeaks 3 years ago
      According to this link ANAB gets 8-25% royalties from Dostarlimab. This drug has recently shown phenomenal results in a trial at Memorial Sloan Kettering Hospital. All patients fully recovered from rectal cancer.
      https://www.globenewswire.com/fr/news-release/2020/10/26/2114250/0/en/AnaptysBio-and-GlaxoSmithKline-Amend-Strategic-Immuno-Oncology-Collaboration.html
      👍️0
      TFMG TFMG 4 years ago

      $ANAB | #Anaptysbio Spikes After Drug Designation


      Nice spike in the afterhours session, lets hope we
      can get some continuation tomorrow.
      Target $29.00 to Fib Golden Pocket
      Also a very large gap to fill at $35.00
      AnaptysBio gets orphan drug designation of imsidolimab for pustular psoriasis
      PLEASE GIVE US A LIKE IF YOU FIND OUR CONTENT HELPFUL, THANK YOU.


      👍️0
      LoveItInBishop LoveItInBishop 5 years ago
      RSI @ 16. laughable. Zacks has positive take. https://finance.yahoo.com/news/anaptysbio-enters-oversold-territory-135501475.html
      👍️0
      ClayTrader ClayTrader 5 years ago
      * * $ANAB Video Chart 11-13-19 * *

      Link to Video - click here to watch the technical chart video

      👍️0
      ClayTrader ClayTrader 5 years ago
      * * $ANAB Video Chart 11-08-19 * *

      Link to Video - click here to watch the technical chart video

      👍️0
      waterchaser waterchaser 5 years ago
      LOL! Twitter PnD. Buyer beware.
      👍️0
      420man 420man 5 years ago
      Once the real bounce starts it will be fast....
      👍️0
      Crazy Money Crazy Money 5 years ago
      $10 to da moon
      👍️0
      420man 420man 5 years ago
      This will bounce..... 15 AH
      👍️0
      RJ Trotts RJ Trotts 5 years ago
      trying to bounce back over $11, hoping for more
      👍️0
      TaxiCaT TaxiCaT 5 years ago
      Ouch -
      👍️0
      celle celle 6 years ago
      Nothing happen here?
      👍️0
      manny371 manny371 7 years ago
      This stock is making noise! Bought in Sept $ANAB
      👍️0

      Your Recent History

      NASDAQ
      ANAB
      AnaptysBio
      LSE
      89BZ
      07mar2033c
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads